517 related articles for article (PubMed ID: 20154039)
1. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
[TBL] [Abstract][Full Text] [Related]
2. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
3. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
4. Extremely high levels of CA19-9 and CA125 antigen in benign mucinous ovarian cystadenoma.
Ye C; Ito K; Komatsu Y; Takagi H
Gynecol Oncol; 1994 Feb; 52(2):267-71. PubMed ID: 7508878
[TBL] [Abstract][Full Text] [Related]
5. Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case-control study.
Cho HY; Kyung MS
Med Sci Monit; 2014 Jul; 20():1334-9. PubMed ID: 25073801
[TBL] [Abstract][Full Text] [Related]
6. [Expression of the cdx2 gene in benign intestinal-type mucinous ovarian tumors].
Gaggero G; Sola S; Mora M; Fulcheri E
Pathologica; 2003 Aug; 95(4):185-91. PubMed ID: 14577202
[TBL] [Abstract][Full Text] [Related]
7. MRI appearances of borderline ovarian tumours.
Bent CL; Sahdev A; Rockall AG; Singh N; Sohaib SA; Reznek RH
Clin Radiol; 2009 Apr; 64(4):430-8. PubMed ID: 19264189
[TBL] [Abstract][Full Text] [Related]
8. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
Mann DV; Edwards R; Ho S; Lau WY; Glazer G
Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
[TBL] [Abstract][Full Text] [Related]
9. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
10. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
[TBL] [Abstract][Full Text] [Related]
11. Mucin gene transcripts in benign and borderline mucinous tumours of the ovary: an in situ hybridization study.
Boman F; Buisine MP; Wacrenier A; Querleu D; Aubert JP; Porchet N
J Pathol; 2001 Mar; 193(3):339-44. PubMed ID: 11241413
[TBL] [Abstract][Full Text] [Related]
12. Primary ovarian mucinous tumors with signet ring cells: report of 3 cases with discussion of so-called primary Krukenberg tumor.
McCluggage WG; Young RH
Am J Surg Pathol; 2008 Sep; 32(9):1373-9. PubMed ID: 18670351
[TBL] [Abstract][Full Text] [Related]
13. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
14. Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.
Evans MF; McDicken IW; Herrington CS
J Pathol; 1999 Sep; 189(1):53-9. PubMed ID: 10451488
[TBL] [Abstract][Full Text] [Related]
15. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and prognosis of mucinous tumors of the ovary.
Kikkawa F; Nawa A; Kajiyama H; Shibata K; Ino K; Nomura S
Gynecol Oncol; 2006 Oct; 103(1):171-5. PubMed ID: 16546243
[TBL] [Abstract][Full Text] [Related]
17. Malignant or borderline mucinous cystic neoplasms have a larger number of loculi than mucinous cystadenoma: a retrospective study with MR.
Okamoto Y; Tanaka YO; Tsunoda H; Yoshikawa H; Minami M
J Magn Reson Imaging; 2007 Jul; 26(1):94-9. PubMed ID: 17659568
[TBL] [Abstract][Full Text] [Related]
18. Mucinous tumors of the ovary: a review.
Hart WR
Int J Gynecol Pathol; 2005 Jan; 24(1):4-25. PubMed ID: 15626914
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
20. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
